Lab Information

Talat Bessissow (MD/MSc)

Investigator
Clinical Research Unit
Department of Medicine (McGill)

Research Profile

 Fundamental: 0%
 Clinical: 100%
 Epidemiology: 0%
 Evaluation: 0%
 This email address is being protected from spambots. You need JavaScript enabled to view it.

Keywords

Crohn's disease • ulcerative colitis • mucosal healing • neoplasia • pathogenesis

Research Interests

My research focuses on the role of mucosal healing in the treatment of inflammatory bowel diseases. I am also looking at identifying factor that predict disease relapse.


Team Members

Name Position

Latest Publications

  1. Qatomah, A., Bessissow, A., Chen, Y.-I., Bessissow, T. & Benmassaoud, A. (2025). Management of Refractory Esophageal Variceal Bleeding when TIPSS Is Not Possible: Review of a Challenging Case. Case reports in gastroenterology, vol. 19, p. 67-71.
  2. Ngew, E., Kollipara, R., Bessissow, T., Karboune, S. & George, S. (2025). Nanoencapsulation enhanced the performance of β-carotene for ameliorating inflammation in patient-derived organoids. Nanomedicine (London, England), p. 1-13.
  3. Candel, I., Wetwittayakhlang, P., Bessissow, T. & Lakatos, P. L. (2025). The Importance of Post-Inflammatory Polyps (PIPs) in Colorectal Cancer Surveillance in Inflammatory Bowel Diseases. Journal of clinical medicine, vol. 14.
  4. Shehab, M., Al-Hindawi, A., Alrashed, F., Murthy, S., Bisschops, R., Hoentjen, F., Barkun, A., Singh, S. & Bessissow, T. (2025). Network Meta-Analysis: Comparison of Endoscopic Dysplasia Detection Technologies in Inflammatory Bowel Disease. Alimentary pharmacology & therapeutics.
  5. Farkas, B., Bessissow, T., Limdi, J. K., Sethi-Arora, K., Kagramanova, A., Knyazev, O., Bezzio, C., Armuzzi, A., Lukas, M., Michalopoulos, G., Chaskova, E., Savarino, E. V., Castiglione, F., Rispo, A., Schäfer, E., Saibeni, S., Filip, R., Attauabi, M., Fousekis, F. S., Bacsur, P., Resál, T., Bálint, A., Ivány, E., Szepes, Z., Bősze, Z., Fábián, A., Bor, R., Farkas, K., Lakatos, P. L. & Molnár, T. (2024). Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn's Disease: A Retrospective, Multicentre Study. Journal of clinical medicine, vol. 13.
  6. Solitano, V., Narula, N., Ma, C., Nanayakkara, A., Suarez, K. E., Zoughlami, A., Guizzetti, L., Bessissow, T. & Jairath, V. (2024). Effectiveness of Ustekinumab for patients with moderate to severe Ulcerative Colitis: A Multi-Center Real-World Canadian Study. The American journal of gastroenterology.
  7. Di Fonzo, D. M. P., Alabdulkarim, B., Yanofsky, R., Abduallah, Y., Golovics, P., Lakatos, P. L., Bitton, A., Wild, G., Afif, W. & Bessissow, T. (2024). Association Between Serum Ustekinumab Concentrations and Endoscopic Disease Activity in Moderate-to-Severe Crohn's Disease Patients. Crohn's & colitis 360, vol. 6, p. otae071.
  8. Abbas, A., Di Fonzo, D. M. P., Wetwittayakhlang, P., Al-Jabri, R., Lakatos, P. L. & Bessissow, T. (2024). Management of ulcerative colitis: where are we at and where are we heading?. Expert review of gastroenterology & hepatology, p. 1-8.
  9. Bacsur, P., Resál, T., Sarlós, P., Iliás, Á., Dalma Sümegi, L., Kata, D., Dávid, A., Farkas, B., Ivány, E., Bálint, A., Bősze, Z., Fábián, A., Bor, R., Szepes, Z., Afif, W., Bessissow, T., Farkas, K., Lakatos, P. L. & Molnár, T. (2024). Outcomes of treatment cessation after switching to subcutaneous vedolizumab treatment in inflammatory bowel diseases. Therapeutic advances in gastroenterology, vol. 17, p. 17562848241290636.
  10. Shehab, M. & Bessissow, T. (2024). Editorial: Advancing care in Crohn's disease-Time to standardise bowel preparation scales. Alimentary pharmacology & therapeutics, vol. 60, p. 1455-1456.
More on PubMed 



See also

Card image
Peter
Lakatos


See profile
Card image
Waqqas
Afif


See profile
Card image
Alain
Bitton


See profile
Card image
Paul
Brassard


See profile
Card image
Jean-Pierre
Routy


See profile
Card image
Giada
Sebastiani


See profile